Japan MedPeer Survey: Daiichi Sankyo’s Inavir Market Share Increases To 34%
This article was originally published in PharmAsia News
Executive Summary
During the 2013-14 influenza season in Japan, 46.5% of doctors are still prescribing Chugai’s Tamifl to patients, while 34.1% prescribe Daiichi Sankyo’s Inavir, according to a recent study.